COMMUNIQUÉS West-GlobeNewswire

Pharming Group to participate in June investor conferences
03/06/2024
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month [...]
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
03/06/2024
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer [...]
Number of voting rights as of May 31, 2024
03/06/2024
Nicox SA Société anonyme with a registered capital of € 502,996.94 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On June 3 rd , 2024, MONTHLY [...]
Nombre de droits de vote au 31 mai 2024
03/06/2024
Nicox SA Société anonyme au capital de 502 996,94 euros Siège social : Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410 Biot R.C.S. ANTIBES 403.942.642 Le 03 juin 2024, PUBLICATION MENSUELLE DU [...]
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
03/06/2024
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan PARIS, FRANCE, 3 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services [...]
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
03/06/2024
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés et son nouveau plan d’actionnariat salarié PARIS, FRANCE, 3 juin 2024 - Ipsen (Euronext: IPN; ADR: [...]
New data with daridorexant to be presented at SLEEP 2024
03/06/2024
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at [...]
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
03/06/2024
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented new data from [...]
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
03/06/2024
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03/06/2024
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the Pertinence Invest 2 Fund [...]
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03/06/2024
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement ( via le fonds Pertinence [...]
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
03/06/2024
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol [...]
Mesoblast Corporate Presentation at Investor Conference
03/06/2024
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that [...]
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
03/06/2024
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) ( [...]
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
03/06/2024
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the [...]
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
02/06/2024
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates p atients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination [...]
Le congrès de l’EAACI débute à Valence, en Espagne
02/06/2024
La médecine personnalisée, l’immunothérapie et l’intelligence artificielle (IA) : des thèmes clés VALENCE, Espagne, 02 juin 2024 (GLOBE NEWSWIRE) -- Le congrès international de l’EAACI a débuté sous le slogan « [...]
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
02/06/2024
The HEAD registry, with nearly 800 patients, serves to evaluate the economic and social impact of allergies at a European level VALENCIA, Spain, June 02, 2024 (GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ [...]
Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®
02/06/2024
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 02 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade [...]

Pages